Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer

Cancer Science

Volumn 103, Issue 2, 2012, Pages 176-180

  Fujimura, Tetsuya ^a   Takahashi, Satoru ^b   Urano, Tomohiko ^a,c   Tanaka, Toshiya ^d   Zhang, Weiguang ^a   Azuma, Kotaro ^a,c   Takayama, Kenich ^a,c   Obinata, Daisuke ^b   Murata, Taro ^a   Horie Inoue, Kuniko ^e   Kodama, Tatsuhiko ^d   Ouchi, Yasuyoshi ^c   Homma, Yukio ^a   Inoue, Satoshi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e Research Center for Genomic Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; PREGNANE X RECEPTOR;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; CELL LINE; CYTOCHROME P-450 CYP3A; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 84856499075     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02143.x     Document Type: Article

References (24)

1. Niu Y, Chang TM, Yeh S et al. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010; 29: 3593-604.
2. Mendiratta P, Mostaghel E, Guinney J et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2022-9.
3. Mizokami A, Koh E, Fujita H et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutates androgen receptor. Cancer Res 2004; 64: 765-71.
4. Hara T, Nakamura K, Araki H et al. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Cancer Res 2003; 63: 5622-8.
5. Kumagai J, Fujimura T, Takahashi S et al. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer. Prostate 2007; 67: 1029-37.
6. Waxman DJ, Attisano C, Guengerich P et al. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263: 424-36.
7. Waxman DJ, Lapenson DP, Aoyama T et al. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991; 290: 160-6.
8. 3 steroid metabolite in the rat ventral prostate: 5α-androstane-3β, 6α, 17β-triol. Steroids 1979; 33: 639-57.
9. Isaacs JT, McDermott IR, Coffey DS. Characterization of two new enzymatic activities of the rat ventral prostate: 5α-androstane-3β, 6α, 17β-diol 6α-hydroxylase and 5α-androstane-3β, 6α, 17β-diol 7α -hydroxylase. Steroids 1979; 33: 675-92.
10. Sundin M, Warner M, Haaparanta T et al. Isolation and catalytic activity of Cytochrome P-450 from ventral prostate of control rats. J Biol Chem 1987; 262: 12293-7.
11. Parkinson A, Mudra DR, Johnson C et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209.
12. Fujimura T, Takahashi S, Urano T et al. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 2009; 74: 391-7.
13. Di Masi A, De Marinis E, Ascenzi P et al. Nuclear receptors CAR and PXR: molecular, functional, and biochemical aspects. Mol Aspects Med 2009; 30: 297-343.
14. Blumberg B, Sabbagh W, Juguilon H et al. SXR, a novel steroid and xenobiotic- sensing nuclear receptor. Genes Dev 1998; 12: 3195-205.
15. Verma S, Tabb MM, Blumberg B. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer 2009; 9: 3.
16. Ouyang N, Ke S, Eagleton N et al. Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br J Cancer 2010; 102: 1753-61.
17. Ichikawa T, Horie-Inoue K, Ikeda K et al. Steroid and xenobiotic receptor SXR mediates vitamin K2 activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem 2006; 281: 16927-34.
18. Tanaka T, Takeno T, Watanabe Y et al. The generation of monoclonal antibodies against human peroxisome proliferator-activated receptors (PPARs). J Atheroscler Thromb 2002; 9: 233-42.
19. Fujimura T, Takahashi S, Urano T et al. Differential expression of estrogen-related receptors β and γ and their clinical significance in human prostate cancer. Cancer Sci 2010; 101: 646-51.
20. Allred DC, Clark GM, Elledge R et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6.
21. Zang B, Cheng Q, Ou Z et al. Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 2010; 151: 5721-9.
22. Harmsen S, Meijerman I, Beijnen JH et al. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol 2009; 64: 35-43.
23. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 287-95.
24. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.